Clinical Features and Risk Factors of Coagulation Disorders Caused by Cefoperazone Sodium and Sulbactam Sodium
ZHU Yuan-chao1, LIANG Liang2, SHEN Ji2, CHEN Di1, HU Xin1*
1. Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application, Beijing 100730; 2. Department of Geriatric Medicine, Beijing Hospital, Beijing 100730, China
Abstract：OBJECTIVE To find the clinical characteristics and risk factors of coagulation disorders induced by cefoperazone sodium and sulbactam sodium, and provide a basis for rational use of cefoperazone sodium and sulbactam sodium. METHODS A retrospective study was conducted on patients who received cefoperazone sodium and sulbactam sodium from January 2013 to December 2019. The whole therapeutic process was recorded. RESULTS A total of unique 3 259 patients were enrolled in this study, 136 patients experienced coagulation disorder. Coagulation disorders developed 3-15 days after medication, with an average of (6.59±3.24) days, 99.3% (135/136) of the patients had Grade 1-3 adverse reactions. Multivariate logistic regression analysis showed that dose ≥ 95 mg·kg-1, treatment course ≥ 9 days, liver and kidney dysfunction and food intake deficiency were the independent risk factors for coagulation disorders caused by cefoperazone sodium and sulbactam sodium (P<0.05). CONCLUSION Cefoperazone sodium and sulbactam sodium can cause coagulation disorders, and the incidence of moderate adverse reactions is high. For patients underlying more than two risk factors, it is recommended to use vitamin K prophylacticly or choose other antibiotics with less impact on coagulation function.
KATUKURI G R, MADDALA R N, RAMAMOORTHI K, et al. Cefoperazone induced gastrointestinal bleeding[J]. J Clin Diagn Res, 2016, 10(8):OD10-OD11.
[2]
TANG Y, WANG L, MEI D, et al. Analysis of serious adverse drug reactions of anti-infective drugs [J]. Chin Pharm J(中国药学杂志), 2014, 49(22): 2036-2038.
[3]
SHI S P, WU X, NONG J C, et al. Influencing factors of coagulation abnormalities induced by cefoperazone/sulbactam [J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2019, 29(9):578-580.
[4]
NIH. Common terminology criteria for adverse events (CTCAE) [EB/OL]. (2022-03-03). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
[5]
CAI Z, YANG W, HE Y, et al. Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: A case report and review of the literature[J]. Drug Saf Case Rep, 2016, 3(1):Doi:10.1007/s40800-016-0025-9.
[6]
HIRATA N, KANAYA N, S HIMIZU H, et al. Suspicious case of epidural hematoma due to coagulopathy caused by vitamin K deficiency associated with antibiotics[J]. Masui Jpn J Anesthesiol, 2007, 56(2):181-185.
[7]
SHEARER M J, BECHTOLD H, ANDRASS K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status[J]. J Clin Pharmacol, 1988, 28(1): 88-95.
[8]
CHEN L J, HSIAO F Y, SHEN L J, et al. Use of Hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: A nationwide nested case-control study[J]. PLoS One, 2016, 11(7):e0158407. Doi: 10.1371/journal.pone.0158407.eCollection2016.
[9]
LI Y, HU Y F, PENG F C, et al. Evidence-based analysis of thrombocytopenia caused by cefoperazone/sulbactam [J]. Chin Pharm J(中国药学杂志), 2009, 44(23): 1938-1941.
[10]
PARK G H, KIM S, KIM M S, et al. The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2019, 16(20):3937. Doi: 10.3390/ijerph16203937.
[11]
WANG W, LIU Y, YU C, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study[J]. Expert Opin Drug Saf, 2020, 19(3):339-347.
[12]
DU J L, JIAO H M, SUN D, et al. Analysis of relative factors for coagulation abnormalities induced by cefoperazone/sulbactam in elderly patients [J]. Chin J Clin Pharmacol (中国临床药理学杂志), 2016, 32(24):2303-2306.
[13]
WANG L, DING M, LI S, et al. Cefoperazone sodium/sulbactam sodium (2∶1) [J]. Chin J Clin Pharmacol (中国临床药理学杂志), 2006, 22(2): 145-147.
[14]
GREENFIELD R A, GERBER A U, CRAIG W A. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function[J]. Clin Infect Dis, 1983, 5(Suppl 1):S127-S136.
[15]
WANG Y Y, YU J H, DUAN J L. Analysis of influencing factors of coagulation dysfunction caused by cefoperazone sulbactam[J]. Chin Gen Pract (中国全科医学), 2020, 23(S1):138-140.
[16]
ZHANG H Y, WU D, WANG G X, et al. Influencing factors of coagulation abnormalities induced by cefoperazone/sulbactam [J]. Chin Med Rec (中国病案), 2019, 20(6):81-84.
[17]
SATTLER F R, WEITEKAMP M R, SEYEGH A, et al. Impaired hemostasis caused by beta-Iactam antibiotics[J]. Am J Surg, 1988, 155(5): 30-39.
[18]
STROM B L, SCHINNAR R, GIBSON G A, et al. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case [J]. Pharmacoepidemiol Drug Saf, 1999, 8(2):81-94.
2022, Vol. 57 
